Vagus nerve stimulation (VNS) is another treatment option that benefits patients with refractory epilepsy who do not respond to medications and that helps reduce their frequency of ER visits and hospitalization. The whole set of the VNS medical device has been included under NHI coverage by the National Health Insurance Administration (NHIA) since December 1, 2020. To be eligible for VNS implantation, patients must undergo clinical evaluations conducted by doctors to examine their indications. Only patients with refractory epilepsy that cannot be treated through epilepsy surgery or whose surgery treatments had failed can apply for reimbursement of the implantation. The NHIA would allocate its budget of over 60 million NHI points a year. About 100 patients are expected to be benefited from the coverage.